Home pagePRENW • NASDAQ
Prenetics
0,0098 $
Pre-market:
0,010 $
(2,04%)+0,00020
Data e ora chiusura: 31 gen, 20:00:00 GMT-5 · USD · NASDAQ · Disclaimer
Titolo quotato in USA
Chiusura precedente
0,0083 $
Intervallo annuale
0,0042 $ - 0,021 $
Cap di mercato
64,14 Mln USD
Volume medio
28.503,00
Notizie del mercato finanziario
Dati finanziari
Conto economico
Entrate
Utile netto
(USD)set 2024Variazione Y/Y
Entrate
7,78 Mln59,86%
Spese di gestione
15,76 Mln2,99%
Utile netto
-10,67 Mln21,36%
Margine di profitto netto
-137,2150,80%
Utili per azione
EBITDA
-10,71 Mln14,43%
Aliquota fiscale effettiva
0,62%
Totale attivo
Totale passivo
(USD)set 2024Variazione Y/Y
Investimenti cash/breve termine
48,69 Mln-45,29%
Totale attivo
235,77 Mln-14,71%
Totale passivo
55,67 Mln16,88%
Patrimonio netto totale
180,10 Mln
Azioni in circolazione
12,72 Mln
Prezzo/valore contabile
0,00
Redditività dell'attivo
-12,59%
Rendimento sul capitale
-15,54%
Flusso di cassa netto
(USD)set 2024Variazione Y/Y
Utile netto
-10,67 Mln21,36%
Liquidità di esercizio
Contanti da investimenti
Contanti da finanziamenti
Flusso di cassa netto
Flusso di cassa libero
Informazioni
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer. Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Fondazione
2014
Dipendenti
322
Ricerca
Cancella ricerca
Chiudi ricerca
App Google
Menu principale